NCI Awards Cancer Trials Support Unit Contract to Westat Corp.

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

ROCKVILLE, Md-The NCI has awarded the contract to develop and implement the Cancer Trials Support Unit (CTSU) to Westat Corporation (Rockville, Md), a health and social sciences research organization. Westat will work with the Coalition of National Cancer Cooperative Groups and Oracle Corporation’s Health Informatics Consulting Practice.

 ROCKVILLE, Md—The NCI has awarded the contract to develop and implement the Cancer Trials Support Unit (CTSU) to Westat Corporation (Rockville, Md), a health and social sciences research organization. Westat will work with the Coalition of National Cancer Cooperative Groups and Oracle Corporation’s Health Informatics Consulting Practice.

The project’s goals are to streamline and centralize some regulatory and administrative tasks to allow the cancer cooperative groups to concentrate resources on the design and conduct of trials; facilitate access for the general public and health care providers interested in participating in clinical trials; and develop a simplified process for enrolling patients in clinical trials using the CTSU as the single point of entry.

Recent Videos
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content